Opus Genetics (IRD) Cash from Investing Activities Growth (1y) (2011 - 2021)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -114.28% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 826.39% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -674.01% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -166.24% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -122.45% |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -118.55% |
| Dec 31, 2020 | 536.26% |
| Dec 31, 2019 | -106.18% |
| Sep 30, 2019 | -18.13% |
| Jun 30, 2019 | -7.86% |
| Mar 31, 2019 | -296.67% |
| Dec 31, 2018 | 165.30% |
| Sep 30, 2018 | 22.29% |
| Jun 30, 2018 | 132.44% |
| Mar 31, 2018 | 321.98% |
| Dec 31, 2017 | -165.45% |
| Sep 30, 2017 | 257.18% |
| Jun 30, 2017 | -504.38% |
| Mar 31, 2017 | 192.69% |
| Dec 31, 2016 | 209.41% |
| Sep 30, 2016 | -127.39% |
| Jun 30, 2016 | -6.01% |
| Mar 31, 2016 | -118.09% |
| Dec 31, 2015 | -91.50% |
| Sep 30, 2015 | 133.90% |
| Jun 30, 2015 | 3,417.30% |
| Mar 31, 2015 | 14,594.37% |
| Dec 31, 2014 | -822.01% |
| Sep 30, 2014 | -138,357.31% |
| Jun 30, 2014 | -80.65% |
| Mar 31, 2014 | -78.49% |
| Dec 31, 2013 | 135.37% |
| Sep 30, 2013 | -97.28% |
| Jun 30, 2013 | -83.60% |
| Mar 31, 2013 | -14.17% |
| Dec 31, 2012 | -158.15% |
| Sep 30, 2012 | 139.59% |
| Jun 30, 2012 | 247.62% |
| Mar 31, 2012 | 105.28% |
| Dec 31, 2011 | 240.59% |
| Sep 30, 2011 | 157.65% |